Zentalis Pharmaceuticals, Inc. Common Stock ZNTL
$3.88
-0.26%
at last close
Analyst Consensus
- Consensus Rating
- Buy (3 Buy · 1 Hold · 0 Sell)
- Average Price Target
- $8.25
- Implied Upside
- +112.6%
- Price Target Range
- $4.00 – $11.00
- Analysts (12 mo)
- 4
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-07-23 | Rodman & Renshaw |
Initiates coverage on | Buy | $11 |
| 2026-07-17 | MizuhoGraig Suvannavejh |
Initiates coverage on | Outperform | $8 |
| 2026-04-10 | GuggenheimMichael Schmidt |
Maintains | Buy | $6 → $10 |
| 2026-03-27 | GuggenheimMichael Schmidt |
Reiterates | Buy | $6 |
| 2025-11-12 | Morgan StanleyMatthew Harrison |
Maintains | Equal-weight | $8 → $4 |
| 2025-08-07 | Wells FargoDerek Archila |
Maintains | Equal-weight | $6 → $5 |
| 2025-05-15 | WedbushRobert Driscoll |
Reiterates | Neutral | $4 |
| 2025-05-15 | HC Wainwright & Co.Andres Maldonado |
Reiterates | Buy | $10 |
| 2025-03-28 | WedbushRobert Driscoll |
Reiterates | Neutral | $4 |
| 2025-03-27 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $10 |
| 2025-03-17 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $10 |
| 2025-01-30 | Wells FargoDerek Archila |
Maintains | Equal-weight | $8 → $6 |
| 2025-01-29 | HC Wainwright & Co.Andrew Fein |
Maintains | Buy | $20 → $10 |
| 2025-01-28 | UBSEliana Merle |
Maintains | Neutral | $5 → $2 |
| 2024-11-15 | GuggenheimMichael Schmidt |
Maintains | Buy | $12 → $8 |
| 2024-11-15 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $20 |
| 2024-09-16 | OppenheimerMatthew Biegler |
Reiterates | Outperform | $20 |
| 2024-08-12 | WedbushRobert Driscoll |
Upgrades | Underperform → Neutral | $4 |
| 2024-08-12 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $20 |
| 2024-06-20 | UBSEliana Merle |
Downgrades | Buy → Neutral | $28 → $5 |
| 2024-06-18 | Wells FargoDerek Archila |
Downgrades | Overweight → Equal-weight | $29 → $9 |
| 2024-06-18 | StifelBradley Canino |
Maintains | Buy | $32 → $10 |
| 2024-06-18 | HC Wainwright & Co.Andrew Fein |
Maintains | Buy | $40 → $20 |
| 2024-06-18 | OppenheimerMatthew Biegler |
Maintains | Outperform | $50 → $25 |
| 2024-06-18 | Morgan StanleyMatthew Harrison |
Downgrades | Overweight → Equal-weight | $38 → $8 |
| 2024-05-08 | HC Wainwright & Co.Andrew Fein |
Maintains | Buy | $46 → $40 |
| 2024-05-08 | StifelBradley Canino |
Maintains | Buy | $36 → $32 |
| 2024-02-28 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $46 |
| 2024-02-28 | WedbushRobert Driscoll |
Maintains | Neutral | $12 → $15 |
| 2023-11-08 | WedbushRobert Driscoll |
Downgrades | Outperform → Neutral | $38 → $12 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $3.88
- Market Cap
- $367.33 million
- 52-Week Range
- $1.21 – $6.95
- Average Volume
- 1.24 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.